Abstract
Background Early life exposures can increase the risk of both obesity and hypertension in adulthood. In this paper we identify exposures across five pre-hypothesised childhood domains, explore them as predictors of obesity and hypertension comorbidity using the 1958 National Child Development Study (NCDS), and discuss these results in comparison to a similar approach using another birth cohort (the 1970 British Cohort Study (BCS70)).
Methods The analytical sample included 9150 participants. The outcome was obesity (BMI of ≥30) and hypertension (blood pressure>140/90mm Hg) comorbidity at age 44. Domains included: ‘prenatal, antenatal, neonatal and birth’, ‘developmental attributes and behaviour’, ‘child education and academic ability’, ‘socioeconomic factors’ and ‘parental and family environment’. Stepwise backward elimination selected variables for inclusion for each domain, and predicted risk scores of obesity-hypertension for each cohort member within each domain were calculated. We performed multivariable logistic regression analysis including domain-specific risk scores, sex and ethnicity to assess how well the outcome could be predicted taking all domains into account. In additional analysis we included potential adult factors.
Results Including all domain-specific risk scores, sex, and ethnicity in the same prediction model the area under the curve was 0.70 (95%CI 0.67-0.72). The strongest domain predictor for obesity-hypertension comorbidity was for the socioeconomic factors domain (OR 1.28 95%CI 1.18-1.38), similar to the BCS70 results. However, the parental and family environment domain was not a significant predictor for obesity-hypertension comorbidity (OR 1.08 95%CI 0.94-1.24) unlike the BCS70 results. After considering adult predictors, robust associations remained to the socioeconomic, education and academic abilities, development and behaviour, and prenatal, antenatal, neonatal and birth domains.
Conclusions In the NCDS some early life course domains were found to be significant predictors of obesity-hypertension comorbidity, supporting previous findings. Shared early-life characteristics could have a role in predicting obesity-hypertension comorbidity, particularly for those who faced socioeconomic disadvantage.
Competing Interest Statement
RKO is a member of the National Institute for Health and Care Excellence (NICE) Technology Appraisal Committee, member of the NICE Decision Support Unit (DSU), and associate member of the NICE Technical Support Unit (TSU). She has served as a paid consultant to the pharmaceutical industry and international reimbursement agencies, providing unrelated methodological advice. She reports teaching fees from the Association of British Pharmaceutical Industry (ABPI). RBH is a member of the Scientific Board of the Smith Institute for Industrial Mathematics and System Engineering.
Funding Statement
This work is part of the multidisciplinary ecosystem to study lifecourse determinants and prevention of early-onset burdensome multimorbidity (MELD-B) project which is supported by the National Institute for Health Research (NIHR203988). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval for MELD-B was obtained from the University of Southampton Faculty of Medicine Ethics committee (ERGO II Reference 66810).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
